Varian, Inc. Reports Fourth Quarter 20...(--------- --------- --------- --------- ...),Health

Date:11/4/2009

--------- --------- --------- --------- Net cash provided by operating activities 33,558 19,397 112,887 79,021 --------- --------- --------- --------- Cash flows from investing activities Proceeds from sale of property, plant and equipment 344 470 6,454 1,735 Purchase of property, plant and equipment (4,245) (7,286) (25,073) (23,960) Acquisitions, net of cash acquired (20) (2,269) (2,449) (55,167) Private company equity investments - - - (18) --------- --------- --------- --------- Net cash used in investing activities (3,921) (9,085) (21,068) (77,410) --------- --------- --------- --------- Cash flows from financing activities Repayments of debt - - - (6,250) Repurchase of common stock (24) (24,968) (7,647) (106,859) Issuance of common stock 4,856 2,467 8,139 18,228 Excess tax benefit from share-based plans 705 (2,258) 705 894 Transfers to Varian Medical Systems, Inc. (204) - (645) (600) --------- --------- --------- --------- Net cash provided by (used in) financing activities 5,333 (24,759) 552 (94,587) --------- --------- --------- --------- Effects of exchange rate changes on cash and cash equivalents 8,001 (9,872) 13,082 475 --------- --------- --------- --------- Net increase (decrease) in cash and cash equivalents 42,971 (24,319)
'/>"/>

SOURCE Varian, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Related medicine technology :

1. Varian, Inc. to Release Fourth Quarter and Full Fiscal Year 2009 Financial Results
2. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
3. 96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
4. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
5. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
6. Cambrex Reports Third Quarter 2009 Results
7. Regeneron Reports Third Quarter 2009 Financial and Operating Results
8. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
9. Uroplasty Reports Results for Second Quarter FY2010
10. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
11. Mettler-Toledo International Inc. Reports Third Quarter 2009 Results